Nothing Special   »   [go: up one dir, main page]

EA201891186A1 - Антитела, нейтрализующие вирус иммунодефицита человека - Google Patents

Антитела, нейтрализующие вирус иммунодефицита человека

Info

Publication number
EA201891186A1
EA201891186A1 EA201891186A EA201891186A EA201891186A1 EA 201891186 A1 EA201891186 A1 EA 201891186A1 EA 201891186 A EA201891186 A EA 201891186A EA 201891186 A EA201891186 A EA 201891186A EA 201891186 A1 EA201891186 A1 EA 201891186A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
neutralizing
virus
human immunodeficiency
hiv
Prior art date
Application number
EA201891186A
Other languages
English (en)
Inventor
Мини Балакришнан
Брайан А. Карр
Джон Корбин
Крэйг С. Пэйс
Натан Д. Томсен
Сюэ Чжан
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201891186A1 publication Critical patent/EA201891186A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предложены новые антитела к ВИЧ с улучшенными терапевтическими свойствами, связанные фармацевтические композиции и способы их применения.
EA201891186A 2015-12-15 2016-12-14 Антитела, нейтрализующие вирус иммунодефицита человека EA201891186A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267652P 2015-12-15 2015-12-15
PCT/US2016/066658 WO2017106346A2 (en) 2015-12-15 2016-12-14 Human immunodeficiency virus neutralizing antibodies

Publications (1)

Publication Number Publication Date
EA201891186A1 true EA201891186A1 (ru) 2018-12-28

Family

ID=58737847

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091898A EA202091898A1 (ru) 2015-12-15 2016-12-14 Антитела, нейтрализующие вирус иммунодефицита человека
EA201891186A EA201891186A1 (ru) 2015-12-15 2016-12-14 Антитела, нейтрализующие вирус иммунодефицита человека

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202091898A EA202091898A1 (ru) 2015-12-15 2016-12-14 Антитела, нейтрализующие вирус иммунодефицита человека

Country Status (37)

Country Link
US (3) US10239935B2 (ru)
EP (2) EP3992206A1 (ru)
JP (4) JP6732915B2 (ru)
KR (1) KR102165120B1 (ru)
CN (2) CN109311967B (ru)
AR (1) AR106991A1 (ru)
AU (3) AU2016370591C1 (ru)
BR (1) BR112018012164A2 (ru)
CA (1) CA3008442C (ru)
CL (1) CL2018001587A1 (ru)
CO (1) CO2018006050A2 (ru)
CR (1) CR20180321A (ru)
CU (1) CU20180062A7 (ru)
CY (1) CY1124756T1 (ru)
DK (1) DK3390441T3 (ru)
DO (2) DOP2018000146A (ru)
EA (2) EA202091898A1 (ru)
EC (1) ECSP18045028A (ru)
ES (1) ES2897756T3 (ru)
HU (1) HUE056243T2 (ru)
IL (1) IL259832B (ru)
LT (1) LT3390441T (ru)
MA (1) MA44077A (ru)
MX (2) MX2018007288A (ru)
MY (2) MY186414A (ru)
NZ (1) NZ743713A (ru)
PE (1) PE20181451A1 (ru)
PH (1) PH12018501281A1 (ru)
PL (1) PL3390441T3 (ru)
SA (1) SA518391778B1 (ru)
SG (2) SG10202108793TA (ru)
SI (1) SI3390441T1 (ru)
SV (1) SV2018005710A (ru)
TW (2) TWI814056B (ru)
UA (1) UA125819C2 (ru)
WO (1) WO2017106346A2 (ru)
ZA (1) ZA201803783B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
PL3365366T3 (pl) 2015-10-25 2022-01-31 Sanofi Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV
EP3992206A1 (en) 2015-12-15 2022-05-04 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
DK3443006T5 (da) 2016-04-13 2024-09-16 Sanofi Sa Trispecifikke og/eller trivalente bindingsproteiner
CA3020633A1 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CA3065328C (en) 2017-06-21 2023-08-15 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EA202091521A1 (ru) * 2017-12-19 2020-10-22 Дзе Рокфеллер Юниверсити ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
AU2019226034A1 (en) * 2018-02-21 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
WO2019226829A1 (en) * 2018-05-22 2019-11-28 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
CN112334572A (zh) * 2018-06-19 2021-02-05 南特细胞公司 Hiv治疗组合物和方法
JP7126573B2 (ja) 2018-07-03 2022-08-26 ギリアード サイエンシーズ， インコーポレイテッド ＨＩＶ ｇｐ１２０を標的化する抗体および使用方法
WO2020056383A1 (en) * 2018-09-13 2020-03-19 Children's National Medical Center Cells comprising antibodies against human immunodeficiency virus and methods of preparing and using the same
WO2020086782A1 (en) * 2018-10-24 2020-04-30 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv
ES2961791T3 (es) * 2018-12-19 2024-03-13 Humabs Biomed Sa Anticuerpos que neutralizan el virus de la hepatitis B y usos de los mismos
MX2021008207A (es) * 2019-01-07 2021-11-04 Univ Jefferson Proteínas de fusión multifuncionales y usos de las mismas.
JP7265647B2 (ja) 2019-03-22 2023-04-26 ギリアード サイエンシーズ， インコーポレイテッド 有橋三環式カルバモイルピリドン化合物およびその薬学的使用
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TWI762925B (zh) 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
US20220289829A1 (en) * 2019-07-08 2022-09-15 California Institute Of Technology Anti-hiv vaccine antibodies with reduced polyreactivity
AU2020315598A1 (en) 2019-07-16 2022-03-03 Gilead Sciences, Inc. HIV vaccines and methods of making and using
JP7502861B2 (ja) 2019-12-27 2024-06-19 旭化成株式会社 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
WO2021207635A1 (en) * 2020-04-09 2021-10-14 The George Washington University Prussian blue nanoparticles functionalization with latency reversing agents and broadly neutralizing antibodies, and applications thereof
MX2023002194A (es) 2020-08-25 2023-03-03 Gilead Sciences Inc Moleculas multiespecificas de union a antigenos dirigidas al vih y metodos de uso.
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2021377614A1 (en) 2020-11-11 2023-06-22 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
US20230000973A1 (en) * 2021-06-25 2023-01-05 Janssen Vaccines & Prevention B.V. Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment
TW202342448A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
EP4440702A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202402280A (zh) 2022-07-01 2024-01-16 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
WO2024220624A1 (en) 2023-04-19 2024-10-24 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913521B2 (ja) 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
PT81498B (pt) 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US7041293B1 (en) 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
AU2005320349C1 (en) 2004-02-06 2019-06-13 E. R. Squibb & Sons, L.L.C. Antibodies against clostridium difficile toxins and uses thereof
US7871991B2 (en) 2004-07-27 2011-01-18 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
WO2006050219A2 (en) 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101027427B1 (ko) 2004-11-12 2011-04-11 젠코어 인코포레이티드 ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20100056898A1 (en) 2005-06-13 2010-03-04 Mckenna David R Objective Methods of Estimating Age of Animals and Carcasses
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
EP1803814A1 (en) 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
WO2008140579A2 (en) 2006-11-17 2008-11-20 New York University Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope
JP4783325B2 (ja) 2007-04-09 2011-09-28 株式会社神戸製鋼所 高温排ガスの処理方法
EA024359B1 (ru) 2007-06-29 2016-09-30 Джилид Сайэнс, Инк. Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CA2707418C (en) 2007-11-16 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
PL2313111T3 (pl) 2008-08-01 2014-08-29 Ventirx Pharmaceuticals Inc Preparaty agonistów receptora Toll-podobnego i ich zastosowanie
CN102272158B (zh) 2008-11-12 2014-05-07 乔治·K·刘易斯 源自记忆b细胞的人单克隆抗体的快速表达克隆
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
AU2010215872A1 (en) 2009-02-20 2011-09-01 International Aids Vaccine Initiative Vesicular stomatitis virus vectors encoding HIV Env epitopes
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
EP2246364A1 (en) 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US8691809B2 (en) 2009-08-18 2014-04-08 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
CA2771484C (en) 2009-08-18 2019-01-15 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
SG10201406813RA (en) 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
AP2013006707A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds
CA2802308C (en) 2010-07-02 2018-08-28 Lianhong Xu Napht-2-ylacetic acid derivatives to treat aids
CN102374226A (zh) 2010-08-06 2012-03-14 深圳富泰宏精密工业有限公司 套筒、铰链结构及应用该铰链结构的便携式电子装置
CA3109036C (en) 2010-08-31 2023-08-01 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
KR101479886B1 (ko) 2010-09-28 2015-01-06 후지쯔 가부시끼가이샤 공존 동작 모드를 활성화시키는 방법 및 기지국, 사용자 장비 및 시스템
WO2012045090A2 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Therapeutic use of a tlr agonist and combination therapy
MX351464B (es) 2010-10-01 2017-10-16 Ventirx Pharmaceuticals Inc Star El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
KR101416437B1 (ko) 2010-11-03 2014-07-10 한국전자통신연구원 파장 가변 외부 공진 레이저 발생 장치
EP2640720B1 (en) 2010-11-18 2018-10-17 Yale University, Inc. Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
BR112013017943A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores receptores do tipo toll
BR112013017947A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores de receptor toll-like
WO2012106578A1 (en) * 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
SI3330257T1 (sl) 2011-04-08 2020-07-31 Janssen Sciences Ireland Unlimited Company Derivati pirimidina za zdravljenje virusnih okužb
KR20140027295A (ko) 2011-04-21 2014-03-06 길리애드 사이언시즈, 인코포레이티드 벤조티아졸 화합물 및 이들의 약학적 용도
UA114476C2 (uk) 2011-05-18 2017-06-26 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
ES2797123T3 (es) 2011-12-21 2020-12-01 Novira Therapeutics Inc Agentes antivirales para la hepatitis B
IN2014MN01736A (ru) 2012-02-08 2015-07-10 Janssen R & D Ireland
CN105121418A (zh) 2012-04-20 2015-12-02 吉利德科学公司 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途
US11149069B2 (en) 2012-08-03 2021-10-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
CN109232439A (zh) 2012-08-10 2019-01-18 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的烷基嘧啶衍生物
JP6293765B2 (ja) 2012-10-10 2018-03-14 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症および他の疾患の処置のためのピロロ［３，２−ｄ］ピリミジン誘導体
BR112015011036B1 (pt) 2012-11-16 2022-02-01 Janssen Sciences Ireland Uc Derivados de 2-amino-quinazolina substituídos heterocíclicos, composição farmacêutica
SI3608325T1 (sl) 2012-12-21 2022-09-30 Gilead Sciences, Inc. Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba
RU2015131006A (ru) 2012-12-27 2017-01-30 Джапан Тобакко Инк. ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ)
WO2014124457A1 (en) * 2013-02-11 2014-08-14 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
ES2733361T3 (es) 2013-02-21 2019-11-28 Janssen Sciences Ireland Unlimited Co Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
CA2932405A1 (en) 2013-12-02 2015-06-11 Aaron Diamond Aids Research Center Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
CN106714800B (zh) * 2014-07-11 2021-09-03 吉利德科学公司 用于治疗hiv的toll样受体调节剂
PL3097102T3 (pl) 2015-03-04 2018-04-30 Gilead Sciences Inc Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
EP3992206A1 (en) 2015-12-15 2022-05-04 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies

Also Published As

Publication number Publication date
CY1124756T1 (el) 2022-07-22
AR106991A1 (es) 2018-03-07
CN109311967B (zh) 2022-03-04
UA125819C2 (uk) 2022-06-15
AU2016370591C1 (en) 2020-09-03
SG11201804787UA (en) 2018-07-30
US10882898B2 (en) 2021-01-05
TWI735491B (zh) 2021-08-11
US20210155676A1 (en) 2021-05-27
US11655285B2 (en) 2023-05-23
CA3008442C (en) 2022-03-08
ECSP18045028A (es) 2018-06-30
CN109311967A (zh) 2019-02-05
JP2022000025A (ja) 2022-01-04
BR112018012164A2 (pt) 2018-12-04
AU2016370591A1 (en) 2018-07-12
WO2017106346A2 (en) 2017-06-22
US10239935B2 (en) 2019-03-26
US20190211083A1 (en) 2019-07-11
LT3390441T (lt) 2021-11-10
EA202091898A1 (ru) 2021-06-22
ES2897756T3 (es) 2022-03-02
JP2019506142A (ja) 2019-03-07
CN114848812A (zh) 2022-08-05
TW201731870A (zh) 2017-09-16
SI3390441T1 (sl) 2021-11-30
DK3390441T3 (da) 2021-10-11
US20170190763A1 (en) 2017-07-06
WO2017106346A3 (en) 2017-09-21
JP6732915B2 (ja) 2020-07-29
AU2021261910A1 (en) 2021-12-02
PL3390441T3 (pl) 2022-01-10
DOP2021000022A (es) 2021-02-28
CR20180321A (es) 2018-08-21
TW202222826A (zh) 2022-06-16
EP3390441A2 (en) 2018-10-24
CL2018001587A1 (es) 2018-09-28
JP6936361B2 (ja) 2021-09-15
SA518391778B1 (ar) 2021-09-07
AU2021261910B2 (en) 2024-04-18
AU2019275625A1 (en) 2020-01-02
DOP2018000146A (es) 2018-06-30
KR20180085804A (ko) 2018-07-27
MY196200A (en) 2023-03-22
MX2018007288A (es) 2018-09-28
EP3992206A1 (en) 2022-05-04
NZ743713A (en) 2020-01-31
SG10202108793TA (en) 2021-09-29
JP7126594B2 (ja) 2022-08-26
TWI814056B (zh) 2023-09-01
PH12018501281A1 (en) 2019-02-04
ZA201803783B (en) 2019-08-28
SV2018005710A (es) 2018-09-19
IL259832A (en) 2018-07-31
JP2020120689A (ja) 2020-08-13
EP3390441B1 (en) 2021-08-25
PE20181451A1 (es) 2018-09-12
MX2022013524A (es) 2022-11-16
IL259832B (en) 2022-06-01
HUE056243T2 (hu) 2022-02-28
CO2018006050A2 (es) 2018-06-20
KR102165120B1 (ko) 2020-10-13
CA3008442A1 (en) 2017-06-22
MY186414A (en) 2021-07-22
AU2016370591B2 (en) 2019-09-12
JP2022163192A (ja) 2022-10-25
CU20180062A7 (es) 2018-08-06
AU2019275625B2 (en) 2021-09-09
MA44077A (fr) 2021-05-05

Similar Documents

Publication Publication Date Title
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201790495A1 (ru) Фармацевтические композиции длительного действия
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
JOP20180058A1 (ar) أجسام مضادة محيدة لفيروس نقص المناعة البشرية
EA202091619A2 (ru) Антитела против tigit